Yael Cohen, MD
TASMC · Tel-Aviv Sourasky Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yael Cohen, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:04 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04813653 · Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma CellsTel-Aviv Sourasky Medical Center · completed · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory · principal investigator
- Ph2NCT04790474 · Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and BortezomibTel-Aviv Sourasky Medical Center · active not recruiting · Multiple Myeloma in Relapse, Refractory Multiple Myeloma · principal investigator
- Ph2NCT04065789 · Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsTel-Aviv Sourasky Medical Center · completed · Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.